Compare PTGX & STN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | STN |
|---|---|---|
| Founded | 2006 | 1954 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 7.7B |
| IPO Year | 2016 | 2005 |
| Metric | PTGX | STN |
|---|---|---|
| Price | $139.40 | $67.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $174.69 | $98.53 |
| AVG Volume (30 Days) | ★ 535.2K | 224.7K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,078.44 | $9.16 |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | $60.03 | ★ $28.96 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $62.24 | $66.26 |
| 52 Week High | $160.81 | $114.52 |
| Indicator | PTGX | STN |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 34.05 |
| Support Level | $132.37 | $66.83 |
| Resistance Level | $142.20 | $71.43 |
| Average True Range (ATR) | 4.59 | 1.50 |
| MACD | -0.44 | -0.33 |
| Stochastic Oscillator | 39.61 | 6.46 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.